Fosigotifator, an amyotrophic lateral sclerosis drug developed by Calico Life Sciences, a biotech company backed by Google’s parent company Alphabet, failed to meet its primary endpoint, according to topline results from the Healey ALS platform trial.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
